Opinion

Malware naming – a never ending story

Last week there was some coverage about a new P2P worm, which is highly polymorphic and infects other files.

Many antivirus vendors detected this piece of malware as Polipos, and this name has been widely used.

But should the worm really be called this?

The body of the worm contains the following text:

Win32.Polipos v1.2 by Joseph

Calling this piece of malware Polipos, which most antivirus vendors are doing, raises an ethical dilemma.

On the one hand, there’s a high degree of uniformity.

Changing the name could lead to a situation similar to that with Nyxem/Blackworm/CME-24; no one wants to see that naming confusion repeated.

On the other hand, there’s a serious ethical dilemma: One of the antivirus industry’s unwritten rules is that malware should never be called by the name the author intended.

We’ve therefore decided to rename this worm from Polipos to Polip, and I hope that other antivirus vendors will follow suit.

Malware naming – a never ending story

Your email address will not be published. Required fields are marked *

 

Reports

Lyceum group reborn

According to older public researches, Lyceum conducted operations against organizations in the energy and telecommunications sectors across the Middle East. In 2021, we have been able to identify a new cluster of the group’s activity, focused on two entities in Tunisia.

GhostEmperor: From ProxyLogon to kernel mode

While investigating a recent rise of attacks against Exchange servers, we noticed a recurring cluster of activity that appeared in several distinct compromised networks. With a long-standing operation, high profile victims, advanced toolset and no affinity to a known threat actor, we decided to dub the cluster GhostEmperor.

APT trends report Q2 2021

This is our latest summary of advanced persistent threat (APT) activity, focusing on significant events that we observed during Q2 2021: attacks against Microsoft Exchange servers, APT29 and APT31 activities, targeting campaigns, etc.

Subscribe to our weekly e-mails

The hottest research right in your inbox